{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:46:55Z","timestamp":1789962415128,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T00:00:00Z","timestamp":1386115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Case Reports"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1016\/j.ebcr.2013.12.002","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T00:00:21Z","timestamp":1388793621000},"page":"8-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Myoclonus in renal failure: Two cases of gabapentin toxicity"],"prefix":"10.1016","volume":"2","author":[{"given":"Kenneth R.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amay","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Bridgeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milisha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebcr.2013.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","article-title":"Antiepileptic drugs in the treatment of psychiatric disorders","volume":"21","author":"Kaufman","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 7","key":"10.1016\/j.ebcr.2013.12.002_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","article-title":"Why are antiepileptic drugs used for nonepileptic conditions?","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0015","article-title":"Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment","author":"Anderson","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0020","first-page":"559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"Mack","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0091270012439209","article-title":"Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil","volume":"53","author":"Lai","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.0013-9580.2005.20804.x","article-title":"Gabapentin-induced myoclonus in end-stage renal disease","volume":"46","author":"Zhang","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1526-4637.2008.00492.x","article-title":"Gabapentin toxicity in renal failure: the importance of dose adjustment","volume":"10","author":"Miller","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0149-2918(03)90011-7","article-title":"Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials","volume":"25","author":"Backonja","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0050","first-page":"CD007938","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"3","author":"Moore","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","article-title":"Ca2+ channel \u03b12\u03b4 ligands: novel modulators of neurotransmission","volume":"28","author":"Dooley","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/j.1552-4604.1995.tb05020.x","article-title":"Disposition of gabapentin in anuric subjects on hemodialysis","volume":"35","author":"Wong","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1528-1157.2000.tb00192.x","article-title":"Myoclonus associated with the use of gabapentin","volume":"44","author":"Asconape","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.amjmed.2009.09.030","article-title":"Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity","volume":"123","author":"Zand","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2008.1268","article-title":"Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia","author":"Hung","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0971-4065.83744","article-title":"Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy","volume":"22","author":"Guddati","year":"2012","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0085","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2147\/NDT.S1715","article-title":"Clinical use of pregabalin in the management of central neuropathic pain","volume":"3","author":"Finnerup","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0095","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1528-1157.2001.44000.x","article-title":"Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin","volume":"42","author":"Huppertz","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0100","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.22286","article-title":"Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure","volume":"24","author":"Healy","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0105","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/j.ajkd.2009.04.014","article-title":"Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure","volume":"54","author":"Yoo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00415-005-0970-1","article-title":"Gabapentin-induced severe myoclonus in a patient with impaired renal function","volume":"253","author":"Holtkamp","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ebcr.2013.07.002","article-title":"Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior","volume":"1","author":"Kaufman","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0120","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs \u2014 best practice guidelines for therapeutic drug monitoring: a position paper for the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neucli.2006.12.006","article-title":"Symptomatic myoclonus","volume":"36","author":"Borg","year":"2006","journal-title":"Neurophysiol Clin"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1542-4758.2009.00358.x","article-title":"Metformin-induced encephalopathy without lactic acidosis in a patient with contraindications for metformin","volume":"13","author":"Jung","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0135","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.neuro.2007.05.004","article-title":"First time, low dose citalopram use-related serotonin syndrome","volume":"28","author":"Turedi","year":"2007","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10072-011-0546-z","article-title":"Serotonin toxicity: a short review of the literature and two case reports involving citalopram","volume":"32","author":"Talarico","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0145","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1212\/WNL.54.10.2022","article-title":"Myoclonus secondary to albuterol (salbutamol) instillation","volume":"54","author":"Mitcheli","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0150","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.amjmed.2008.10.036","article-title":"Amlodipine-induced myoclonus","volume":"122","author":"Wallace","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0155","article-title":"Myoclonus associated with concomitant ciprofloxacin and oxycodone in an older patient","author":"Gopinath","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0160","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/jpm.2011.0103","article-title":"Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone","volume":"14","author":"Paramanandam","year":"2011","journal-title":"J Palliat Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00228-011-1077-5","article-title":"Potentially inappropriate drug prescriptions in the elderly in France: a population-based study from the French National Insurance Healthcare system","volume":"67","author":"Bongue","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0170","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00228-012-1238-1","article-title":"Potentially inappropriate medications in the elderly: a comprehensive protocol","volume":"68","author":"Matanovic","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/postgradmedj-2012-130889","article-title":"The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease","volume":"89","author":"Jones","year":"2013","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0180","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/AAP.0b013e3181df2645","article-title":"Duloxetine: a review of its pharmacology and use in chronic pain management","volume":"35","author":"Bellingham","year":"2010","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.ebcr.2013.12.002_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Epilepsy & Behavior Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213323213000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213323213000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:54:14Z","timestamp":1761980054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213323213000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":37,"alternative-id":["S2213323213000480"],"URL":"https:\/\/doi.org\/10.1016\/j.ebcr.2013.12.002","relation":{},"ISSN":["2213-3232"],"issn-type":[{"value":"2213-3232","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myoclonus in renal failure: Two cases of gabapentin toxicity","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebcr.2013.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}